FGF-basic

Product Information
Primary Accession	XP_035600424.1
Species	Salmon
Sequence	Full length
Purity	≥ 95% as analyzed by SDS-PAGE
Endotoxin Level	< 0.2 EU/ µg of protein by gel clotting method
Biological Activity	EC₅₀ < 1.0 ng/ml as determined by a dose-response proliferation assay using murine Balb/c 3T3 cells. Based on the EC₅₀, the calculated specific activity is approximately > 1.0 × 10⁶ IU/mg. It is recommended to experimentally determine the optimal concentration for each specific application by performing a dose response assay.
Expression System	E. coli
Theoretical Molecular Weight	17.1 kDa
Formulation	Lyophilized from a 0.2 µm filtered solution in 7.8 mM Na₂HPO₄, 1.5 mM KH₂PO₄, 2.7 mM KCl, 500 mM NaCl.
Reconstitution	Before opening, centrifuge the vial briefly to bring the contents to the bottom. Reconstitute the lyophilized powder in PBS up to 100 µg/ml.
Storage & Stability	Upon receiving, the lyophilized product remains stable for up to 6 months at lower than -70 °C. Upon reconstitution, the product is stable for up to 1 week at 4 °C or up to 3 months at -20 °C. Avoid repeated freeze-thaw cycles by making single-use aliquots before the solution is storage at -20 °C.

Additional Information
Target Background	Fibroblast Growth Factor-basic (FGF-basic), also known as FGF-2, is a pleiotropic cytokine and one of the prototypic members of the heparin-binding FGF family. Like other FGF family members, FGF-basic has the β trefoil structure. In vivo, FGF-basic is produced by a variety of cells, including cardiomyocytes, fibroblasts, and vascular cells. FGF-basic regulates a variety of processes including cell proliferation, differentiation, survival, adhesion, motility, apoptosis, limb formation and wound healing. FGF-basic can be tumorigenic due to its role in angiogenesis and blood vessel remodeling. The angiogenic effects of FGF-basic can produce beneficial cardioprotection during acute heart injury.